issues for mr, page-2

Ramses thank you for sharing and my simplified assessment of the company and view of events as folows:

1 Excellent management and products - 9/10
2 ASX300 inclusion - 6.5/10
3 NASDAQ listing after annual report to ASX/NASDAQ due end of month and therefore expect ann by end of oct - 8/10
4 Positive interim Phase2B update ann before end of year -7/10
5 Dubai sales starts by end of year - 7/10
6 If treatment is successful and sales in Australia/Europe - 9.5/10
7 Completion of Phase3 recruitment - 6.5/10
8 Final FDA approval/worldwide sales - 10/10

Above all IMHO and GL to all SH